[Influence of plasmatic testosterone during natural history of prostate cancer: a review].

[1]  A. Masson-Lecomte,et al.  A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA , 2013, World Journal of Urology.

[2]  V. Bini,et al.  Low serum testosterone levels are predictive of prostate cancer , 2013, World Journal of Urology.

[3]  A. Alcaraz,et al.  Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment , 2012, BJU international.

[4]  G. Hackett.  Testosterone and the heart , 2012, International journal of clinical practice.

[5]  F. Iellamo,et al.  Testosterone and heart failure , 2012, Endocrine.

[6]  M. Rouprêt,et al.  Critères cliniques et biologiques pertinents pour poser un diagnostic de déficit androgénique lié à l’âge (DALA) , 2012 .

[7]  M. Rouprêt,et al.  Influence de l'âge sur la santé sexuelle masculine , 2012 .

[8]  A. Alcaraz,et al.  Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy , 2012, World Journal of Urology.

[9]  O. Cussenot,et al.  [Active surveillance for the secondary prevention of prostate cancer]. , 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[10]  S. Johansson,et al.  Androgen Deprivation Therapy and the Risk of Coronary Heart Disease and Heart Failure in Patients with Prostate Cancer , 2011, Drug safety.

[11]  P. Camparo,et al.  High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. , 2011, The Journal of urology.

[12]  A. Hoznek,et al.  Low pretreatment total testosterone (<3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer , 2011, BJU international.

[13]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[14]  M. Peyromaure,et al.  Recommandations en Onco-Urologie 2010 : Cancer de la prostate , 2010 .

[15]  Choung-Soo Kim,et al.  Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level? , 2010, BJU international.

[16]  A. Vis,et al.  Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α‐reductase , 2009, BJU international.

[17]  M. Matsumura,et al.  The androgen‐regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma , 2008, The Journal of pathology.

[18]  P. Kantoff,et al.  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Roddam,et al.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. , 2008, Journal of the National Cancer Institute.

[20]  G. Cancel-Tassin,et al.  Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. , 2007, European urology.

[21]  A. Orsola,et al.  Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.

[22]  Y. Ishikawa,et al.  Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. , 2007, European urology.

[23]  O. Cussenot,et al.  Impact de l'obésité sur le PSA lors du dépistage du cancer de la prostate , 2007 .

[24]  H. Raff,et al.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. , 2007, The Journal of clinical endocrinology and metabolism.

[25]  D. English,et al.  Circulating Steroid Hormones and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[26]  G. Bartsch,et al.  Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. , 2005, Endocrine-related cancer.

[27]  D. Rossi,et al.  Physiologie des androgènes chez l'homme adulte , 2004 .

[28]  J. Reginster,et al.  Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. , 2004, European journal of endocrinology.

[29]  O. Cussenot,et al.  Prevention of prostate cancer by androgens: experimental paradox or clinical reality. , 2004, European urology.

[30]  P. Stattin,et al.  High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study , 2004, International journal of cancer.

[31]  Jason C. Massengill,et al.  Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. , 2003, The Journal of urology.

[32]  O. Cussenot,et al.  Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. , 2002, European journal of endocrinology.

[33]  G. Kramer,et al.  High‐grade prostate cancer is associated with low serum testosterone levels , 2001, The Prostate.

[34]  C. Mantzoros,et al.  Hormonal predictors of prostate cancer: a meta-analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Vatten,et al.  Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  R. Santen,et al.  Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[38]  Mottet Nicolas,et al.  前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .

[39]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.